{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Ulcerative+Colitis&page=2", "query": { "condition": "Severe Ulcerative Colitis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Ulcerative+Colitis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T15:17:54.601Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04033445", "title": "A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1064, "start_date": "2019-09-26", "completion_date": "2027-07-16", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 52, "location_summary": "Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033445" }, { "nct_id": "NCT02144350", "title": "Hyperbaric Oxygen for Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Hyperbaric oxygen", "type": "PROCEDURE" }, { "name": "Sham Hyperbaric Air", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2018-04-06", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Lebanon, New Hampshire • Pittsburgh, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144350" }, { "nct_id": "NCT02435992", "title": "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "RPC1063", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1012, "start_date": "2015-06-17", "completion_date": "2020-06-17", "has_results": true, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 113, "location_summary": "Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435992" }, { "nct_id": "NCT02760615", "title": "Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colitis, Ulcerative", "Crohn Disease" ], "interventions": [ { "name": "Caffeine", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2016-11-01", "completion_date": "2020-08-01", "has_results": false, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 2, "location_summary": "Cypress, California • Miami, Florida", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760615" }, { "nct_id": "NCT02100696", "title": "A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrozulimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 609, "start_date": "2014-05-21", "completion_date": "2020-04-16", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 38, "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100696" }, { "nct_id": "NCT03518086", "title": "An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Mirikizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1281, "start_date": "2018-06-18", "completion_date": "2024-05-15", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 98, "location_summary": "Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518086" }, { "nct_id": "NCT01971814", "title": "Early Serum Infliximab Levels in Severe Ulcerative Colitis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis (UC)", "Inflammatory Bowel Disease" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-11", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-05-29", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01971814" }, { "nct_id": "NCT04996797", "title": "A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Tulisokibart", "type": "DRUG" }, { "name": "Companion Diagnostic (CDx) Testing", "type": "DEVICE" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2021-07-14", "completion_date": "2025-07-14", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 29, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996797" }, { "nct_id": "NCT01959282", "title": "A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "JNJ-54781532 25 mg once daily", "type": "DRUG" }, { "name": "JNJ-54781532 75 mg once daily", "type": "DRUG" }, { "name": "JNJ-54781532 150 mg once daily", "type": "DRUG" }, { "name": "JNJ-54781532 75 mg twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2013-11-15", "completion_date": "2015-12-05", "has_results": false, "last_update_posted_date": "2019-01-04", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 15, "location_summary": "La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Thornton", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Tupelo", "state": "Mississippi" }, { "city": "Egg Harbor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959282" }, { "nct_id": "NCT04277546", "title": "Open-label Extension Study of Brazikumab in Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Brazikumab Maintenance Dose", "type": "DRUG" }, { "name": "Brazikumab Induction Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 57, "start_date": "2020-03-03", "completion_date": "2023-10-10", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-28T15:17:54.601Z", "location_count": 10, "location_summary": "Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04277546" } ] }